Milestone Pharmaceuticals (MIST) reaches agreement with Alta Advisers

Jul 05, 2024

∙ Paid

Key Summary: On November 9, 2023, Alta Advisers (5%) expressed concern to the Board about potential non-value maximizing funding options for Etripamil. On July 14, 2024, they entered a Cooperation Agreement, leading the company to expand its Board and appoint Stuart M. Duty and Andrew R. Saik as Initial New Directors until the 2024 Annual Meeting.

M.Cap:…

This post is for paid subscribers

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts

Snowball Research

Milestone Pharmaceuticals (MIST) reaches agreement with Alta Advisers

This post is for paid subscribers